NORSTM as an upper airway “disinfectant”
SaNOtize has demonstrated the effectiveness of its NORSTM formulation in eradicating different types of viruses, including influenza and H1N1, and is working diligently to determine its efficacy for preventing and treating COVID-19 infections.
At present, SaNOtize:
- Has received Health Canada approval and initiated a multi-center, randomized, controlled, phase II efficacy study (N=210) evaluating NORS TM for the prevention and treatment of COVID-19 in healthcare workers and individuals at risk of infection;
- Has confirmed that NORSTM is >99.9% effective against different types of coronaviruses (including SARS-CoV-2, the virus that causes COVID-19) in tests conducted by the independent Institute for Antiviral Research at Utah State University;
- Has applied to the FDA for Emergency Utilization Authorization in adults with an emphasis on availability for healthcare workers; and
- Is working on an IND to allow a clinical trial in the US